International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts - FullText - Breast Care 2020, Vol. 15, No. 1 - Karger Publishers
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts - FullText - Breast Care 2020, Vol. 15, No. 1 - Karger Publishers
Advanced Breast Cancer
Brustkrebs: Adaptive Randomisierung beschleunigt Entwicklung neuer...
Mammakarzinom: Update 2019
Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie | SpringerLink
Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. - Abstract - Europe PMC
Neratinib-basierte Kombination zeigt Wirksamkeit bei HR+, HER2-mutiertem metastasiertem Brustkrebs - Germanic Nachrichten
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts - FullText - Breast Care 2020, Vol. 15, No. 1 - Karger Publishers
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). - Abstract - Europe PMC
PDF) Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
Brustkrebs Brustkrebslauf Brust Krebs Geschenk' Snapback Cap | Spreadshirt
Ergebnisse der CONTROL-Studie zeigen eine verbesserte Verträglichkeit von NERLYNX® (Neratinib) mit allen untersuchten Durchfall-Prophylaxe-Strategien
Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. - Abstract - Europe PMC
Puma Biotechnology und Pierre Fabre schließen exklusiven Lizenzvertrag zur Entwicklung und Vermarktung von NERLYNX® (Neratinib) in Europa ab | Business Wire